- Home
- BFST vs PHAT Comparison
BFST vs PHAT Comparison
Compare BFST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BFST | PHAT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | 842 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 877.1M | 894.0M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BFST | PHAT |
|---|---|---|
| Price | $26.78 | $12.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $32.75 | $19.83 |
| AVG Volume (30 Days) | 136.2K | ★ 1.4M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | 23.45 | ★ 42.72 |
| EPS | ★ 0.68 | N/A |
| Revenue | $10,704,000.00 | ★ $175,110,000.00 |
| Revenue This Year | $22.71 | $93.04 |
| Revenue Next Year | $5.02 | $58.91 |
| P/E Ratio | $39.88 | ★ N/A |
| Revenue Growth | 1.20 | ★ 216.93 |
| 52 Week Low | $22.56 | $3.69 |
| 52 Week High | $30.32 | $18.31 |
Technical Indicators
Market Signals| Indicator | BFST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 48.15 |
| Support Level | $26.78 | $10.38 |
| Resistance Level | $28.18 | $12.52 |
| Average True Range (ATR) | 0.54 | 0.98 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 15.08 | 61.97 |
Price Performance
Historical ComparisonAbout BFST Business First Bancshares Inc.
Business First Bancshares Inc is a bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates the majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.